COVID-19

News

Could-artificial-intelligence-replace-pharma-reps

MHRA looks to AI to hunt for COVID-19 vaccine side effects

The UK drugs regulator has awarded a £1.5 million tender to a software company for an artificial intelligence tool that will be used to process “the expected high volume of COVID-19 vaccine

Views & Analysis

Deep Dive: Digital Health Innovation 2020

Most of the digital health experts we spoke to for this issue of Deep Dive made one thing clear – no one can really say what the future holds for digital tech in the pharma and healthcare i

Views & Analysis

AI’s infiltration of pharma: How COVID-19 accelerated change

The pharmaceutical industry has sometimes been a laggard in terms of digital maturity, but the COVID-19 crisis has provided companies the impetus to rapidly implement the most cutting-edge

News

Moderna banks $1.1bn in COVID-19 vaccine deposits, signs Jap...

Moderna is still preparing for the launch of its COVID-19 vaccine mRNA-1273 – assuming phase 3 trials go to plan – but has already received $1.1 billion in deposits for the shot.

Views & Analysis

Ipsen’s UK & Ireland MD on adapting business to COVID-19

Since entering the pharmaceutical industry as a graduate trainee in the late 1990s, Asad Mohsin Ali’s career has taken him across the business from Novartis, MSD and Tesaro, before joining

News

Gilead Q3 revenue rise bolstered by $873m Veklury sales

Gilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment with its Veklury antiviral, and its latest financial results reveal the benefit of that a

MHRA looks to AI to hunt for COVID-19 vaccine side effects

Deep Dive: Digital Health Innovation 2020

AI’s infiltration of pharma: How COVID-19 accelerated change

Moderna banks $1.1bn in COVID-19 vaccine deposits, signs Jap...

Ipsen’s UK & Ireland MD on adapting business to COVID-19

Gilead Q3 revenue rise bolstered by $873m Veklury sales

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

COVID-19

Editor's Picks